Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
- PMID: 21576639
- PMCID: PMC3422534
- DOI: 10.1200/JCO.2010.32.0630
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Abstract
Mycosis fungoides (MF) and Sézary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
![Fig A1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3422534/bin/zlj9991012990001.gif)
Similar articles
-
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).Blood. 2007 Sep 15;110(6):1713-22. doi: 10.1182/blood-2007-03-055749. Epub 2007 May 31. Blood. 2007. PMID: 17540844 Review.
-
Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.Eur J Cancer. 2018 Apr;93:47-56. doi: 10.1016/j.ejca.2018.01.076. Epub 2018 Feb 21. Eur J Cancer. 2018. PMID: 29477101 Review.
-
TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).Blood. 2007 Jul 15;110(2):479-84. doi: 10.1182/blood-2006-10-054601. Epub 2007 Mar 5. Blood. 2007. PMID: 17339420
-
A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.Skin Therapy Lett. 2012 Dec;17(10):5-9. Skin Therapy Lett. 2012. PMID: 23223768 Review.
-
Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.J Clin Oncol. 2010 Nov 1;28(31):4730-9. doi: 10.1200/JCO.2009.27.7665. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855822
Cited by
-
Tumor flare reaction in a patient with mycosis fungoides treated with a novel immune-epigenetic doublet.JAAD Case Rep. 2024 Apr 7;48:18-22. doi: 10.1016/j.jdcr.2024.03.016. eCollection 2024 Jun. JAAD Case Rep. 2024. PMID: 38741658 Free PMC article. No abstract available.
-
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.Blood Adv. 2024 May 28;8(10):2400-2404. doi: 10.1182/bloodadvances.2023011030. Blood Adv. 2024. PMID: 38531062 Free PMC article. No abstract available.
-
A Case Report of Mycosis Fungoides Presenting With Blister Formation.Cureus. 2024 Feb 14;16(2):e54213. doi: 10.7759/cureus.54213. eCollection 2024 Feb. Cureus. 2024. PMID: 38496187 Free PMC article.
-
Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for Mycosis Fungoides and Sezary Syndrome.Bone Marrow Transplant. 2024 Jun;59(6):874-879. doi: 10.1038/s41409-024-02236-z. Epub 2024 Mar 12. Bone Marrow Transplant. 2024. PMID: 38472408 Free PMC article.
-
Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome (BIO-MUSE): Protocol for a Translational Study.JMIR Res Protoc. 2024 Apr 4;13:e55723. doi: 10.2196/55723. JMIR Res Protoc. 2024. PMID: 38436589 Free PMC article.
References
-
- Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Blood. 2007;110:1713–1722. - PubMed
-
- Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785. - PubMed
-
- Lutzner M, Edelson R, Schein P, et al. Cutaneous T-cell lymphomas: The Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med. 1975;83:534–552. - PubMed
-
- Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: Clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139:857–866. - PubMed
-
- Bunn PA, Jr, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep. 1979;63:725–728. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical